All In MedTech

Device Trial Radar · NCT07016815

Accelerated Optimization of Foundational Medical Therapy in Acute Decompensation of Heart Failure by Telemonitoring: A Pragmatic Multi-center Randomized and Cost-Effectiveness Study

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Jan 1, 2027

Primary completion

Dec 1, 2028

Study completion Feb 28, 2029

Sponsor

Lead sponsor
Chinese University of Hong KongAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 12, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Supportive care
FDA-regulated device
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Problem: Aggressive titration of guideline-directed medical therapy is the cornerstone of heart failure management to reduce heart failure related hospitalization and mortality. A major hurdle to uptitration of medical therapy is the safety concerns of these medications namely hypotension and bradycardia. Early and frequent clinic visits will be required to ensure the safe uptitration of these treatments, but this is difficult to implement in daily practice due to resources constrain. Advancement in wearable and wireless technologies enables remote and continuous monitoring of patients in ambulatory setting and potentially achieving safe and effective uptitration of medical therapy while minimizing the demand on the current healthcare system. However, access to these wearable and wireless technologies is not universal and patients in low socio-economic tiers might be deprived of the opportunity to realize the benefits from these technologies. Solution: This project therefore aims to develop a mobile platform and to provide wearable devices to patients with acute heart failure to improve and optimize the use of guideline-directed medical therapy in these patients. Impacts: The finding from this project will inform future heart failure management and help to implement and integrate telemedicine in the vulnerable stage of heart failure care. It will help to maximize healthcare resources utilization and help to bridge the gap between those who have limited access to healthcare services. The model of heart failure care generated from this project can be propagate and replicated in general patients care.

Conditions

  • Acute Heart Failure With Reduced Left Ventricular Ejection Fraction

Interventions

  • Wearable wrist heart rate and activity monitorDevice

    A commercially available smart watch capable of continuous monitoring of heart rate and activities including daily steps count and daily activity level, detection of arrythmia using a proprietary FDA approved algorithm14, and measuring peripheral capillary oxygen saturation will be provided to the patient. Patients will be encouraged to wear the watch as often as possible during daytime and during sleep. Data gathered will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patient.

  • Bluetooth enabled body weight scale with bioimpedance analysisDevice

    An electronic scale which measures bioimpedance using bioelectrical analysis from foot-to-foot impedance and body fluid percentage (BF%) using a proprietary equation15,16 will be provided to the patients. Patient will be encouraged to measure their bodyweight (BW) and bioimpedance twice per day, one in the morning, and one before bath, with minimal clothing. Both data will be automatically transmitted wirelessly to a cloud-based platform provided by the manufacturer accessible only by the research team and the patients.

  • Bluetooth enabled electronic blood pressure deviceDevice

    An electronic cuffed arm blood pressure monitor will be provided to the patient with instruction on how to perform proper blood pressure measurement at home16. Patients are encouraged to take at least 2 blood pressure reading daily, one in the morning and one in the evening. Blood pressure reading will be transmitted wirelessly to an online platform provided by the manufacturer accessible only by the research team and the patients.

  • mobile applicationDevice

    a mobile Application through which data from remote monitoring and wearables will be incorporated, and instruction for medication titration and education on heart failure management will be provided to the patients.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of patients achieving left ventricular reverse remodeling (LVRR) at 90 days.Time frame: 90 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Prince of Wales Hospital

    Hong Kong, Hong Kong · Recruiting

  • Prince of Wales Hospital

    Hong Kong, Hong Kong · Not yet recruiting

  • Princess Margaret Hospital

    Hong Kong, Hong Kong · Not yet recruiting

5 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.